TMEM106B

Across TCGA pan-cancer cohorts, TMEM106B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM106B data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM106B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM106B expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where TMEM106B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.638	0.872	<.001	70	view →
CCRCC	DFS	Quartile	II,III,IV	0.236	0.741	<.001	51	view →
HNSC	DFS	Median	All	0.993	0.913	.009	32	view →
LUAD	DFS	Quartile	II,III,IV	0.229	0.657	.007	13	view →
OV	DFS	Median	All	0.605	0.977	.035	4	view →
UCEC	OS	Tertile	All	1.000	0.888	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM106B–PDAC (DFS)

Open the PDAC breakdown →